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Abstract
The endocannabinoid system has emerged as a signiﬁcant player in the control of energy balance and
metabolism, through its direct central and peripheral effects, as well as via its interaction with other
appetite-regulating pathways. There is mounting evidence that the endocannabinoid system is
overactive in obesity and were it possible to safely dampen-down the elevated endocannabinoid tone,
lipid and carbohydrate proﬁles could be improved and weight loss induced. The series of randomised
clinical trials showed reproducible beneﬁcial effects on weight, HbA1c and lipid parameters, in addition
to other cardiovascular risk factors. However, to date, clinical developments have been halted because
of psychiatric side effects. Although recent evidence has highlighted the importance of an appetite-
independent, peripheral mode of action, it is still unclear whether selectively blocking the peripheral
system could potentially solve the problem of the central side effects, which thus far has led to the
demise of the cannabinoid antagonists as useful pharmaceuticals. In this concise review, we
summarise the data on the metabolic effects of the cannabinoid pathway and its antagonists.
European Journal of Endocrinology 161 655–662
Introduction
The endocannabinoid system is a complex physiologic
system that is highly relevant in the control of energy
balance and metabolism (1). Upon stimulation,
it increases food intake and weight gain, promotes
lipogenesis and impairs glucose tolerance (2).T h e r ei s
growing evidence that the endocannabinoid system is
overactive in obesity (3, 4), and thus targeting and
suppressing the system could result in a potential
pathway by which to treat obesity, type 2 diabetes and
the metabolic syndrome. Despite the early promising
results of the cannabinoid antagonists, the drug’s side
effect proﬁle regarding depression and suicidal risk has
been deemed unsafe, and thus, to date, all preparations
havebeenwithdrawnfromtrialsorclinicalpractice.Here,
we discuss the discovery, physiology and mechanism of
action of the endocannabinoid system, along with its
potential for manipulation in the treatment of obesity.
The discovery and physiology of the
endocannabinoids
The plant Cannabis sativa has been used to promote
caloric intake by enhancing appetite for hundreds
of years (5, 6). Despite knowledge of its medical
beneﬁts for centuries, it was not until 1964 that the
psychoactive component of cannabis was isolated as
D-9-tetrahydrocannabinol (7), which subsequently led
to the discovery and cloning of two speciﬁc Gi/o protein-
coupled cannabinoid receptors, CB1 (8) and CB2 (9).
Both receptors are expressed in the CNS, as well as in
peripheral tissues. CB1 was found to be one of the most
prevalent G protein-coupled receptors in the mamma-
lian brain, while CB2 was shown to have prominent
roles in immune and haematopoietic cells, as well as
osteoblasts and osteoclasts (10–13). The discovery of
speciﬁc cannabinoid receptors implied that endogenous
ligands capable of activating these receptors must exist.
Anandamide and 2-arachidonoylglycerol (2-AG) are
the two most widely studied ‘endocannabinoids’. They
are not stored in vesicles like other neurotransmitters,
but produced on demand by Ca
2C-induced enzymatic
cleavage from phospholipid precursors (14).C B 1
receptors are often localised on pre-synaptic neurons,
which suggest retrograde signal transmission (15)
(Fig. 1), whereby the endocannabinoids usually act to
reduce neuronal excitability via inhibitory effects on
voltage-gated Ca
2C channels and the activation of K
C
channels (16) (Fig. 2). In addition to CB1 and CB2,
several other receptors were shown to be targets of
endocannabinoids, including the transient receptor
potential cation channel, subfamily V, member 1
(TPRV1) (17), a novel orphan cannabinoid receptor
GPR55 (18) and additional unidentiﬁed endothelial and
cardiac receptors, which may mediate endocannabi-
noid-induced cardiovascular effects (19, 20).
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systemsincludingmood,cognitionandreward,immune,
gastrointestinal and reproduction, sleep, neuroprotec-
tion, bone and cardiovascular function, in addition to
appetite, lipid and carbohydrate metabolism (15). The
orexigenic effect of the endocannabinoids is mediated
via activation of AMP-activated protein kinase (AMPK)
(21–23). AMPK plays a central role in the control of
energy homeostasis both at an individual cellular level
and that of the whole body via its appetite-stimulating
effectsinthehypothalamus.Itcansensethecellular‘energy
status’anduponactivation causes the cell to switch from
ATP consumption to ATP production. AMPK is known
to be inﬂuenced by various stimuli such as leptin,
ghrelin, adiponectin and a-melanocortin-stimulating
hormone, as well as metformin and glitazones (24).
Figure 1 Upon stimulation of the postsynaptic
cell, an inﬂux of intracellular calcium results in the
activation of N-acylphosphatidylethamolamine
hydrolysing phospholipase D (NAPE–PLD) and
diacyl–glycerol lipase (DAGL-a and -b) and
release of endocannabinoids (e.g. anandamide
(ANA) or 2-arachidonoylglycerol (2-AG)) from the
postsynaptic terminal. The endocannabinoid
crosses the synaptic cleft and binds to
its receptor on the presynaptic terminal.
Cannabinoid receptor activation often results in
blocked neurotransmitter release from the
presynaptic neuron. The endocannabinoids are
taken up by the postsynaptic cell via a method of
unspeciﬁed transport (green crescents) and are
ﬁnally inactivated and degraded by fatty acid
amide hydrolase (FAAH) or monoacylglycerol
lipase (MAGL) (83, 84).
Figure 2 Cannabinoid receptor activation
often leads to reduced cellular neuro-
transmission by blocking Ca
2C entry, via
hyperpolarisation,asaresultofK
Cchannel
activation,orbyreducedcAMP generation.
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systems
It seems that cannabinoids interact with a number of
hormonal systems and possibly mediate their effects.
Data for heterodimerisation of the receptor with the
orexin (25), type 2 dopamine (26) and opioid receptors
(27) have been shown, and possible other partners have
been suggested, such as the ghrelin receptor (28)
(Table 1).
Mode of action: central versus peripheral
Initially, it was thought that the endocannabinoid
system acted solely centrally through its effects on
appetite and food intake. In support of this, the CB1
receptor is widely prevalent centrally (8, 42), and
central administration of anandamide into the ventro-
medial nucleus causes hyperphagia in rats (22).
However, the endocannabinoids not only act centrally
but also peripherally in the control of energy balance
and metabolism. CB1 receptors have been found
peripherally on the nerve terminals of gastrointestinal
tract neurons (43), liver (44), skeletal muscle (45),
pancreas (46) and in adipose tissue (47). Upon pair
feeding of CB1 knockout (CB1
K/K) mice with normal
littermates, wild-type mice gained weight, while the
CB1
K/K did not, despite the same caloric intake (48).
Similarly, chronic injection of a CB1 receptor antagonist
in obese rodents caused signiﬁcant weight loss, which
was sustained despite only a transient decrease in
caloric intake (49). A human study showed an increase
in caloric intake and weight gain in volunteers who
smoked cannabis when compared with controls (50);
interestingly, although the weight of the participants
continued to increase throughout the 3-week study,
the increased food intake subsided after just a few days.
This suggests that the cannabinoids increase weight
by methods other than solely stimulating appetite. In
addition, food deprivation leads to a sevenfold increase
in intestinal levels of anandamide, and this effect is
reversed upon refeeding. When the neurotoxin capsai-
cin was used to destroy the sensory afferent ﬁbres of the
gut, the effects of peripherallyadministered anandamide
were abolished. This is supportive of a peripheral
mechanism of action, whereby anandamide acts on
peripheral CB1 receptors located on the sensory nerve
terminals of the gut to create its hyperphagic effect (51).
Furthermore, experimental evidence on adipose tissue
has shown that, in addition to CB1 receptors, enzymes
regulating the biosynthesis and degradation of the
endocannabinoids are present, and the levels of
endocannabinoids in adipose tissue were found to be
similar to those of the brain (52). This is probably due to
an increase in the fat oxidation rate. First, this is
supported by a reduction in the respiratory quotient.
Secondly, experiments in adipocytic cultures have
shown that chronic CB1 blockade reduces adipose
mass by increasing oxidation rate, via the induction of
enzymes of b-oxidation and the Krebs cycle (53).
Thirdly, in the opposite situation, adipocyte cultures
treated with cannabinoid agonists show lipoprotein
lipase activation (2) and decreased expression of
adiponectin (54), which cause triglyceride re-
esteriﬁcation and reduce fatty acid oxidation. Most of
these effects can be explained by the inhibitory effect of
cannabinoids on liver and adipose tissue AMPK activity
(23). Osei-Hyiaman et al. investigated the role of the
liver as a target for the peripheral regulation of energy
metabolism by the endocannabinoids. When given a
high-fat diet, the density of CB1 receptors increased, as
didlevelsofhepaticanandamide.Uponactivation,denovo
fatty acid synthesis occurred (48) due to an increase in
fatty acid synthase and acetyl-CoA carboxylase, thus
promoting insulin resistance and hepatic steatosis (55).
Table 1 Interaction with other hormones and systems.
Interacting partners Effect Reference
Leptin † Leptin reduces endocannabinoid levels in the hypothalamus (30–33)
† Leptin-deﬁcient animals reduce food intake in response to a CB1 antagonist
† Leptin-deﬁcient animals have high endocannabinoid levels
† Anorexia nervosa patients have high circulating endocannabinoid levels
Ghrelin † Ghrelin increases endocannabinoid levels in the hypothalamus (28)
† Intact CB1 is necessary for ghrelin appetite and AMPK effects in the hypothalamus
Adiponectin † CB1 antagonist increases adiponectin levels (30, 34)
† The beneﬁcial effects of CB1 antagonist are partly (but not fully) via adiponectin
NPY, aMSH † Anandamide increases hypothalamic neuropeptide Y, an effect inhibited by
cannabinoid antagonists
(35–36)
† a-MSH and the cannabinoid system have been shown to decrease food intake
synergistically
Orexin † Orexin receptor, OX1R, was shown to heterodimerise with the CB1 receptor, leading
to increased orexin effects
(25, 37)
Glucocorticoids † Glucocorticoids release endocannabinoids in the hypothalamus (38, 39, 82)
Neurotransmitters † The endocannabinoid system inﬂuences the release of various neurotransmitters,
including GABA, noradrenaline, dopamine, glutamate and acetylcholine
(29, 40, 41)
† A direct interaction of dopamine receptors and CB1 has been suggested
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reduce hepatic steatosis in rats (56), while results of
treatment with rimonabant for non-alcoholic fatty liver
disease in humans have been promising (57).
Hyperactivity of the endocannabinoid
system in obesity
Both animal and human data show that the endocan-
nabinoid system is up-regulated in obesity (58).
A signiﬁcantly higher amount of 2-AG was found in
visceral fat in obese and overweight individuals when
compared with normal-weight controls (54). A studyon
obese, postmenopausal women showed raised 2-AG and
anandamide levels, along with reduced fatty acid amide
hydrolase (FAAH) expression compared with control
subjects (59), suggesting that impaired degradation of
endocannabinoids could play a role. Further data to
support the importance of endocannabinoid degra-
dation showed that a missense polymorphism in
FAAH was found to correlate with body mass index
(BMI) in obese patients (60). Those with the poly-
morphism had only half the FAAH enzymatic activity of
controls, thus providing substantial evidence for an
upregulation of the endocannabinoid system in obesity
due to, at least in part, a defect in the mechanism of
degradation (60). However, these data were not
reproduced in a similar study, which included over
5000 patients (61). Polymorphisms of the CNR1 gene
encoding the CB1 receptor have also been shown to be
associated with obesity (62).
Manipulating the system
The hyperactive endocannabinoid system in obesity has
been targeted, using CB1 receptor antagonists, in an
attempt to attenuate endocannabinoid signalling.
Animal studies have shown that by blocking the CB1
receptor, both food intake and weight are signiﬁcantly
reduced (22, 49, 63, 64). Following on from these
promising results, Sanoﬁ-Aventis commenced human
clinicaltrialstotestthesafetyandefﬁcacyofrimonabant
in the treatment of obesity (65). The rimonabant in
obesity (RIO) trials, with over 6600 participants,
composed of four separate trials: RIO North America
(66), RIO Europe (67), RIO Diabetes (68) and RIO Lipids
(69), all published in distinguished journals. Inclusion
criteria for the RIOEuropeand RIONorthAmericatrials
included a BMI O30 kg/m
2 or a BMI O27 kg/m
2 with
obesity-induced disease (66, 67). The RIO Lipids trial
involved hyperlipidaemic, overweight and obese partici-
pants who had previously had no medical therapy, while
the RIO Diabetes trial included type 2 diabetic patients
on monotherapy, who were also overweight or obese.
At 1-year follow-up, the results of the randomised,
double-blind, placebo-controlled trials showed a
placebo-corrected weight loss of 4.7 kg (range 4.1–5.4)
in the 20 mg group in RIO North America and 4.8 kg
(3.9–5.7) in RIO Europe. RIO Lipids reported a weight
loss of 5.4 kg (4.6–6.3), and RIO Diabetes result was
3.9 kg (3.2–4.6) (66–69). Furthermore, HbA1c and
triglyceride levels decreased, while high density lipopro-
tein cholesterol increased. Waist circumference was also
measured in the RIO trials and resulted in statistically
signiﬁcantreductions inthe 20 mggroups(6.1, 6.5,7.1
and 5.2 cm respectively) compared with placebo (2.5,
2.4, 2.4 and 1.9 cm respectively). Further studies
commenced including type 2 diabetic patients with no
previous drug treatment (70), patients on established
diabetic treatment and patients with cardiovascular
risksfactorswerespeciﬁcallyfollowed.Thesestudiesalso
resulted in positive outcomes (71). The data suggested
that rimonabant was a promisingagent, and thus it was
licensed in the European Union (EU) as an anti-obesity
drug and approved by National Institute for Health and
Clinical Excellence for use in the UK. Its indications
were as an adjunct to a healthy diet and exercise in
obese patients (BMI O30 kg/m
2) and for overweight
adults (BMI O27 kg/m
2) with associated risk factors,
such as type 2 diabetes or dyslipidaemia (NICE: National
Institute for Health and ClinicalExcellence: Rimonabant
for the treatment of overweight and obese patients:
http://www.nice.org.uk 2007).
However, a high incidence of adverse effects was
reported in the RIO trials’ 20 mg groups. The most
common side effects reported were headache, nausea,
anxiety and depressed mood (69). Withdrawal rates
were 15.0, 14.5, 12.8 and 15.0% respectively in the
four trials, compared with placebo withdrawal rates of
7.0, 9.2, 7.2 and 5.5% (72). Because of the psycho-
tropic nature of cannabis, psychiatric side effects are
biologically plausible, and indeed 26% of participants in
the 20 mggroups reported psychiatric symptoms. These
included depression, anxiety, sleep disorders and
suicidal ideation (70). However, data suggest that in
real-life clinical practice, w50% of individuals seeking
treatment for obesity also suffer from depression,
making it hard to ascertain whether or not reports of
depression were attributable to the drugor not (73, 74).
As a result of the psychiatric side effect proﬁle, the US
Food and Drug Administration declined permission for
rimonabant, and in October 2008, rimonabant was also
suspended across the EU. The European Medicines
Agency (EMEA) disputed its psychiatric safety, due to
an increased risk of depression and signiﬁcant suicide
risk. Their analysis showed an approximately doubled
risk of psychiatric disorders, including depression,
anxiety, sleep disturbance and suicidal ideation, in
those taking rimonabant when compared with placebo.
Since the withdrawal of rimonabant, other CB1
antagonist drugs have also been halted in the process
of development. Taranabant (Merck & Co.) has been
shown to induce chronic weight loss in diet-induced
obese rats (75, 76). In a human trial, treatment with
12 mg taranabant resulted in a signiﬁcant increase in
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increase in the fat oxidation rate, supported by a
reduction in the respiratory quotient when taking the
drug (77). Although the drug reached phase-III human
obesity trials, they were stopped in October 2008, due to
a high level of central side effects, including anxiety and
depression (EMEA. The European Medicines Agency
recommends suspension of the marketing authorisation
of Acomplia: http://www.emea.europa.eu 2008).
Rimonabant has high afﬁnity binding for the CB1
receptorand actsasafullinverseagonist.Analternative
would be the use of a partial agonist, which would
decrease cannabinoid receptor activation as well as
preventing the psychiatric side effects evident when
completely blocking CB1 (78). Partial agonists are
reported to have a lower prevalence of adverse effects
than either antagonists or inverse agonists, without
reducing the efﬁcacy of the drug (79). An example of
suchadrugwiththepotentialforananti-obesityeffectis
the 5-HT6 ligand, E-6837 (80). The use of partial
agonists at pharmacological targets in the endocanna-
binoid system may produce the signiﬁcant weight loss
results of the cannabinoid antagonists, but without the
psychiatricsideeffects.DataisavailableonaneutralCB1
cannabinoid antagonist, 5-(4-chlorophenyl)-1-(2,4-
dichlorophenyl)-3-hexyl-1H-1,2,4,-triazole-LH21 (81).
Its lackof inverse agonist properties and low permeation
of the blood–brain barrier resulted in an improved side-
effect proﬁle when compared with inverse agonists.
Conclusion
The hyperactive endocannabinoid system established in
obesity has been supported with strong evidence from
both animal and human experiments, with the
argument for a genetic basis especially interesting.
Breaking down the system and blocking the endocan-
nabinoid pathway at any level could potentially
diminish its excessive activity and promote weight
loss. The peripheral actions of the system are intriguing,
and selectively blocking the peripheral receptors may
hold the solution to preventing the central side effects,
which thus far have led to the downfall of the
cannabinoid antagonists in therapeutic medicine.
However, it is currently unclear whether the beneﬁcial
effects on weight, as well as lipid and carbohydrate
metabolism, would be upheld in this case, as convincing
data of direct central regulation of peripheral meta-
bolism are emerging.
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